Boehringer Acquires Rights to Potential CF Inhalation Gene Therapy

Boehringer Acquires Rights to Potential CF Inhalation Gene Therapy

309963

Boehringer Acquires Rights to Potential CF Inhalation Gene Therapy

Boehringer Ingelheim has taken legal steps giving it the lead role in further development of a long-lasting, inhalation gene therapy for cystic fibrosis (CF), called BI 3720931, that stems from a public-private research effort begun in 2018. The 2018 agreement brought together Boehringer, the U.K. Cystic Fibrosis Gene Therapy Consortium (GTC; composed of university scientists), and Oxford Biomedica in work to develop and conduct early tests on a potential first-in-class gene therapy for all with CF. Now, Boehringer…

You must be logged in to read/download the full post.